newsfilter
← Latest News
GlobeNewswire·

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023 Advancing the